Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma

Pelican Therapeutics, a subsidiary of Heat Biologics (NASDAQ:HTBX), entered into a manufacturing agreement with KBI Biopharma for cGMP production of its PTX-35 antibody and PTX-15 fusion protein.
As quoted in the press release:

PTX-35 and PTX-15 have the potential to improve clinical response in combination with Heat’s ImPACT® therapeutic platform and other immunotherapy drugs by simulating the production of antigen-specific T-cells.
“We selected KBI as our manufacturing partner because, based on our assessment, they have strong development capabilities, and possess the agility and flexibility to help Pelican prepare for early development of both our Phase 1 and 2 clinical trials,” said Rahul Jasuja, CEO of Pelican.
Under the agreement, KBI Biopharma will offer comprehensive development and manufacturing services, which Pelican expects will offer advantages such as speed, productivity, stability and flexibility over traditional approaches to cell line development.

Click here to read the full press release.

Source: www.accesswire.com